Identification of Proteomic Biomarkers in Maternal Plasma in the Early Second Trimester That Predict the Subsequent Development of Gestational Diabetes
Restricted accessResearch articleFirst published online February, 2012
Identification of Proteomic Biomarkers in Maternal Plasma in the Early Second Trimester That Predict the Subsequent Development of Gestational Diabetes
Introduction: This study is designed to identify proteomic biomarkers that predict the subsequent development of gestational diabetes mellitus (GDM). Methods: Maternal blood was obtained prospectively from healthy pregnant women in the early second trimester (16-20 weeks). Twelve women subsequently diagnosed with GDM at 24 to 28 weeks were selected as cases; an equal number of normoglycemic women as controls. Proteomic analysis of the previously stored plasma was performed by surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry. Results: Three peaks (9122 Da, 9412 Da, and 9701 Da) that were increased in cases were characterized as isoforms of apolipoprotein CIII. Another discriminatory peak (17 105 Da) that was decreased in cases was matched to apolipoprotein AII. Enzyme-linked immunosorbent assay (ELISA) confirmed that women who subsequently developed GDM had significantly higher levels of apolipoprotein CIII than controls did. Levels of apolipoprotein AII failed to reach statistical significance. Conclusion: Our data suggest that there already exist biomarkers in the maternal circulation at 16 to 20 weeks in women who subsequently develop GDM.
AdamsKMLiHNelsonRLOgburnPLJrDanilenko-DixonDR. Sequelae of unrecognized gestational diabetes. Am J Obstet Gynecol. 1998;178(6):1321–1332.
2.
CaseyBMLucasMJMcIntireDDLevenoKJ. Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population. Obstet Gynecol. 1997;90(6):869–873.
3.
XiongXSaundersLDWangFLDemianczukNN. Gestational diabetes mellitus: prevalence, risk factors, maternal and infant outcomes. Int J Gynaecol Obstet. 2001;75(3):221–228.
4.
LangerOYogevYMostOXenakisEM. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol. 2005;192(4):989–997.
5.
CoustanDRCarpenterMWO'SullivanPSCarrSR. Gestational diabetes: predictors of subsequent disordered glucose metabolism. Am J Obstet Gynecol. 1993;168(4):1139–1144.
6.
YogevYXenakisEMJLangerO. The association between preeclampsia and the severity of gestational diabetes: the impact of glycemic control. Am J Obstet Gynecol. 2004;191(5):1655–1660.
7.
GetahunDNathCAnanthCVChavezMRSmulianJC. Gestational diabetes in the United States: temporal trends 1989 through 2004. Am J Obstet Gynecol. 2008;198(5):525 e1–e5.
8.
GreeneMSolomonC. Gestational diabetes mellitus—time to treat. N Engl J Med. 2005;352(24):2544–2546.
9.
LandonMSpongCThomEA multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339–1348.
10.
BarthaJMartinez-Del-FresnoPComino-DelgadoR. Early diagnosis of gestational diabetes mellitus and prevention of diabetes-related complications. Eur J Obstet Gynecol Reprod Biol. 2003;109(1):41–44.
11.
MetzgerBEBuchananTACoustanDRSummary and recommendations of the fifth international workshop-conference on gestational diabetes mellitus. Diabetes Care. 2007;30(suppl 2):S251–S260.
12.
WeinbergerSRMorrisTSPawlakM. Recent trends in protein biochip technology. Pharmacogenomics. 2000;1(4):395–416.
13.
SundstenTEberhardsonMGoranssonMBergstenP. The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci. 2006;4:22.
14.
SundstenTOstensonCGBergstenP. Serum protein patterns in newly diagnosed type 2 diabetes mellitus—influence of diabetic environment and family history of diabetes. Diabetes Metab Res Rev. 2008;24(2):148–154.
15.
LiuXFengQChenYProteomics-based identification of differentially-expressed proteins including galectin-1 in the blood plasma of type 2 diabetic patients. J Proteome Res. 2009;8(3):1255–1262.
16.
RiazSAlamSSAkhtarMW. Proteomic identification of human serum biomarkers in diabetes mellitus type 2. J Pharm Biomed Anal. 2010;51(5):1103–1107.
17.
ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol. 2001;98(3):525–538.
18.
JensenONMortensenPVormOMannM. Automation of matrix-assisted laser desorption/ionization mass spectrometry using fuzzy logic feedback control. Anal Chem. 1997;69(9):1706–1714.
19.
American Diabetes Association. Gestational diabetes mellitus. Diabetes Care. 2004;27(suppl 1):S88–S90.
20.
DavidssonPHultheJFagerbergBA proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res. 2005;46(9):1999–2006.
21.
WangCSMcConathyWJKloerHUAlaupovicP. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 1985;75(2):384–390.
22.
SehayekEEisenbergS. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991;266(27):18259–18267.
23.
StalenhoefAFDemackerPNLuttermanJAvan't LaarA. Apolipoprotein C in type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia. Diabetologia. 1982;22(6):489–491.
24.
FlorezHMendezACasanova-RomeroPIncreased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population. Atherosclerosis. 2006;188(1):134–141.
25.
BeliardSNogueiraJPMaraninchiMParallel increase of plasma apoproteins C-II and C-III in Type 2 diabetic patients. Diabet Med. 2009;26(7):736–739.
RemaleyATWongAWSchumacherUKMengMSBrewerHBJrHoegJM. O-linked glycosylation modifies the association of apolipoprotein A-II to high density lipoproteins. J Biol Chem. 1993;268(9):6785–6790.
28.
SauvagetDChauffetonVDugue-PujolSIn vitro transcriptional induction of the human apolipoprotein A-II gene by glucose. Diabetes. 2004;53(3):672–678.
29.
Martin-CamposJMEscola-GilJCRibasVBlanco-VacaF. Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility. Curr Opin Lipidol. 2004;15(3):247–253.
30.
Roselli della RovereGLapollaASartoreGPlasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study. Nutr Metab Cardiovasc Dis. 2003;13(1):46–51.
31.
BirjmohunRSDallinga-ThieGMKuivenhovenJAApolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation. 2007;116(18):2029–2035.
32.
OnatAHergencGAyhanEUgurMCanG. Impaired anti-inflammatory function of apolipoprotein A-II concentrations predicts metabolic syndrome and diabetes at 4 years follow-up in elderly Turks. Clin Chem Lab Med. 2009;47(11):1389–1394.
33.
ParkJSOhKJNorwitzERIdentification of proteomic biomarkers of preeclampsia in amniotic fluid using SELDI-TOF mass spectrometry. Reprod Sci. 2008;15(5):457–468.
34.
LeeJParkJSNorwitzERIdentification and characterization of proteins in amniotic fluid that are differentially expressed before and after antenatal corticosteroid administration. Am J Obstet Gynecol. 2010;202(4):388 e1–388 e10.
